Betoptik is a drug that reduces intraocular pressure.
Release form and composition
Betoptik is made in the form of eye drops of 0.5% of a colorless or yellowish tint, in plastic droppers-bottles of 5 ml.
1 ml of the drug contains the active ingredient - betaxolol - in the amount of 5 mg.
Auxiliary substances of the drug are: purified water, benzalkonium chloride, sodium hydroxide solution.
Indications for use
According to the instructions, Betoptik is prescribed to reduce intraocular pressure as the main drug or in combination with other medicines for:
- Ocular hypertension;
- Open-angle glaucoma.
The therapy of these diseases by Betoptik is allowed in patients with pathologies of the respiratory system.
According to the instructions, Betoptik is contraindicated in only one case - in case of hypersensitivity to betaxolol.
In the application Betoptik caution should be exercised when:
- Atrioventricular block 2 and 3 degrees;
- Sinus bradycardia;
- Cardiogenic shock;
- Severe heart failure.
Dosing and Administration
Drops Betoptik intended for local use. The drug is instilled into the conjunctival sac 1-2 drops twice a day.
In some patients, the normalization of intraocular pressure occurs within a few weeks after the initiation of therapy by Betoptik, therefore during the first month of treatment it should be monitored.
In case of insufficient effectiveness of the drug, the patient should consult a doctor for the purpose of additional treatment.
If an excessive amount of the drug gets into the eyes, rinse with water.
The use of Betoptik, as a rule, is well tolerated by patients, and rarely causes side effects. However, patients should be aware that the drug can cause such effects:
- Central nervous system: depressive neurosis, insomnia;
- Organs of vision: lacrimation, short-term discomfort in the eye area after instillation of the drug, redness, dry eyes, reduced corneal sensitivity, photophobia, itching, punctate keratitis, photophobia, anisocoria.
Patients with diabetes Betoptik should be prescribed with caution, as beta-blockers can mask the manifestations of acute hypoglycemia.
Also in the application Betoptik caution should be exercised in patients with thyrotoxicosis, as beta-blockers can hide such a symptom as tachycardia. If the patient has a suspicion of thyrotoxicosis, you should stop taking Betoptik and other beta-blockers.
You should also take into account that beta-blockers can cause symptoms similar to those in myasthenia (general weakness of the body, ptosis, diplopia).
In case of dysfunction of the respiratory system and liver, the development of hypersensitivity to the Betoptik's components is possible.
The use of Betoptik and other beta-blockers should be discontinued two days before any surgical intervention, since during general anesthesia these drugs can reduce the sensitivity of the myocardium to sympathetic stimulation.
Betoptik is prescribed with care to patients with pheochromocytoma and Raynaud's syndrome.
When instillation of the drug into the eyes of the active ingredient Betoptik absorbed into the systemic circulation and can cause as pronounced side effects as with systemic use. Cases of severe cardiovascular and respiratory disorders, including fatal bronchospasm and death from heart failure in patients with bronchial asthma, have been described.
Betoptik practically does not affect the heart rate and blood pressure. However, when prescribing a drug to patients with atrioventricular block, caution should be exercised, and in case of the first signs of decompensation from the cardiovascular system, discontinue treatment.
Betoptiktik is prescribed with caution in combination with adrenergic psychotropic drugs.
Before using eye drops, patients wearing contact lenses should remove and install them no earlier than 20-30 minutes after instillation. The fact is that the preparation contains preservatives that can be deposited in contact lenses and subsequently have a damaging effect on the eye tissue.
Since after instillation into the eyes of patients, there may be a decrease in the clarity of vision, during the period of therapy with Betoptik, one should refrain from controlling potentially dangerous mechanisms that require increased concentration of attention.
Betoptik's combination with other beta-blockers is not recommended, as it causes an increased risk of side effects.
With a combination of eye drops with drugs that deplete catecholamine reserves, a decrease in patient's blood pressure and bradycardia are possible.
There is not enough experience with the drug during pregnancy and breastfeeding, therefore, it is possible to carry out treatment with Betoptik during these periods only if there are strict indications.
Structural analogues of Betoptik drops are:
- Betalmik EU;
- Ksonef BK.
Drugs that have similar pharmacological effects include:
Terms and conditions of storage
According to the instructions, Betoptik belongs to the list of drugs B. Store the drug is recommended in a dark, cool, out of reach of children, not longer than 3 years from the date of issue.
After opening the package, the shelf life of the medicine is 1 month.